var data={"title":"Definition and pathogenesis of left ventricular hypertrophy in hypertension","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Definition and pathogenesis of left ventricular hypertrophy in hypertension</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/contributors\" class=\"contributor contributor_credentials\">Pamela S Douglas, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/contributors\" class=\"contributor contributor_credentials\">Gerald S Bloomfield, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/contributors\" class=\"contributor contributor_credentials\">George L Bakris, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/contributors\" class=\"contributor contributor_credentials\">John P Forman, MD, MSc</a></dd><dd><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/contributors\" class=\"contributor contributor_credentials\">Brian C Downey, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 15, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Left ventricular hypertrophy (LVH) is a common finding in patients with fixed or borderline hypertension and can be diagnosed either by electrocardiography (ECG) or by echocardiography [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Echocardiography is the diagnostic procedure of choice since the sensitivity of the different ECG criteria may be as low as 7 to 35 percent with mild LVH and only 10 to 50 percent with moderate-to-severe disease [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/3\" class=\"abstract_t\">3</a>]. In a report from the Treatment of Mild Hypertension Study, for example, almost none of 844 patients had ECG criteria for LVH, while echocardiographic LVH (indexed by body surface area, see below) was present in 13 percent of men and 20 percent of women [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/4\" class=\"abstract_t\">4</a>]. Nevertheless, if echocardiography is unavailable or too expensive, appropriate ECG criteria can be used to detect increased LV mass [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/5,6\" class=\"abstract_t\">5,6</a>]. (See <a href=\"topic.htm?path=electrocardiographic-diagnosis-of-left-ventricular-hypertrophy\" class=\"medical medical_review\">&quot;Electrocardiographic diagnosis of left ventricular hypertrophy&quot;</a>.)</p><p>The definition and pathogenesis of LVH in hypertension will be reviewed here. The clinical implications of and effects of therapy on this complication and the indications for echocardiography in hypertensive patients are discussed separately. (See <a href=\"topic.htm?path=clinical-implications-and-treatment-of-left-ventricular-hypertrophy-in-hypertension\" class=\"medical medical_review\">&quot;Clinical implications and treatment of left ventricular hypertrophy in hypertension&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">DEFINITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Heart disease resulting from hypertension can be divided into four degrees of severity; LVH defines degree II [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/7\" class=\"abstract_t\">7</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Degree I &ndash; Isolated LV diastolic dysfunction with no LVH</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Degree II &ndash; LV diastolic dysfunction with concentric LVH</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Degree III &ndash; Clinical heart failure (dyspnea and pulmonary edema with preserved ejection fraction)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Degree IV &ndash; Dilated cardiomyopathy with heart failure and reduced ejection fraction</p><p/><p>LVH is defined as an increase in the mass of the left ventricle, which can be secondary to an increase in wall thickness, an increase in cavity size, or both. LVH as a consequence of hypertension usually presents with an increase in wall thickness, with or without an increase in cavity size. This increase in mass predominantly results from a chronic increase in afterload of the LV caused by the hypertension, although there is also a genetic component. A significant increase in the number <span class=\"nowrap\">and/or</span> size of sarcomeres within each myocardial cell is the pathologic mechanism.</p><p>The estimation of LV mass is commonly derived from LV measurements obtained by 2D echocardiography. The American Society of Echocardiography, with the European Association of Echocardiography, has issued the following criteria for LVH using wall thickness and cavity dimensions [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/8\" class=\"abstract_t\">8</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Estimated LV mass of 201 to 227 g (103 to 116 <span class=\"nowrap\">g/m<sup>2</sup>)</span> for men and 151 to 171 g (89 to 100 <span class=\"nowrap\">g/m<sup>2</sup>)</span> for women is mildly abnormal.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Estimated LV mass of 228 to 254 g (117 to 130 <span class=\"nowrap\">g/m<sup>2</sup>)</span> for men and 172 to 193 g (101 to 112 <span class=\"nowrap\">g/m<sup>2</sup>)</span> for women is moderately abnormal.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Estimated LV mass &gt;254 g (&gt;130 <span class=\"nowrap\">g/m<sup>2</sup>)</span> for men and &gt;193 g (&gt;112 <span class=\"nowrap\">g/m<sup>2</sup>)</span> for women is severely abnormal.</p><p/><p>In addition to the absolute increase in mass, the geometric pattern of LVH also may be important [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/9\" class=\"abstract_t\">9</a>]. Patients without an increase in absolute mass, but with an increase in relative wall thickness or in the wall thickness-to-cavity diameter ratio (called concentric remodeling), have the same adverse risk as those with an increase in both mass and relative wall thickness (called concentric hypertrophy). The elevation in risk with either finding is for both cardiovascular disease and death and is independent of the level of blood pressure [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/10\" class=\"abstract_t\">10</a>].</p><p>Hypertension may also result in interstitial fibrosis [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/11\" class=\"abstract_t\">11</a>]. Both factors contribute to an increase in LV stiffness, resulting in diastolic dysfunction and an elevation in LV end diastolic pressure. Glucose intolerance, if present, can contribute to the development of interstitial fibrosis and diastolic dysfunction [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/12\" class=\"abstract_t\">12</a>], presumably due to microvascular ischemia. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-heart-failure-with-preserved-ejection-fraction\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of heart failure with preserved ejection fraction&quot;</a>.)</p><p>Although it is relatively insensitive, the electrocardiography (ECG) does have prognostic significance [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/13\" class=\"abstract_t\">13</a>]. Hypertensive patients with echocardiographically proven LVH who also meet ECG criteria have a greater LV mass than those without the expected ECG changes [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/14\" class=\"abstract_t\">14</a>]. LV mass is highest in those with an ECG &quot;strain&quot; pattern [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/15\" class=\"abstract_t\">15</a>]. Serial monitoring of ECG voltage also may be helpful. In particular, changes in ECG voltage over time may reflect changes in LV mass and correlate with cardiovascular risk. (See <a href=\"topic.htm?path=electrocardiographic-diagnosis-of-left-ventricular-hypertrophy\" class=\"medical medical_review\">&quot;Electrocardiographic diagnosis of left ventricular hypertrophy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOGENESIS OF LVH IN HYPERTENSION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The development of LVH is a relatively early response to hypertension, demonstrable (by echocardiography) in children and adolescents with borderline elevations in blood pressure [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/16\" class=\"abstract_t\">16</a>]. Patients who have exaggerated transient elevations in blood pressure during mental stress (particularly at work) or exercise may be particularly prone to the development of LVH [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/17\" class=\"abstract_t\">17</a>]. Ambulatory blood pressure monitoring has suggested that there may be three additional risk factors for LVH [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/18,19\" class=\"abstract_t\">18,19</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The 24-hour blood pressure load (the proportion of the 24-hour period in which the blood pressure exceeded normal limits [eg, <span class=\"nowrap\">&ge;130/80</span> mmHg during the daytime])</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nocturnal hypertension (average blood pressure <span class=\"nowrap\">&ge;120/70</span> mmHg while asleep)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nocturnal nondipping (in which the expected 10 percent reduction in nighttime blood pressure is not seen)</p><p/><p>Other studies have suggested that the maximal daytime blood pressure or peak exercise blood pressure is most predictive of the level of hypertrophy [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/20\" class=\"abstract_t\">20</a>]. These factors may explain why the ambulatory blood pressure values may correlate more closely with the development of LVH than the casual blood pressure taken in the clinician's office. (See <a href=\"topic.htm?path=ambulatory-and-home-blood-pressure-monitoring-and-white-coat-hypertension-in-adults\" class=\"medical medical_review\">&quot;Ambulatory and home blood pressure monitoring and white coat hypertension in adults&quot;</a>.)</p><p>There is also evidence that LV mass may be increased <strong>prior</strong> to the development of overt hypertension [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/21\" class=\"abstract_t\">21</a>]. Data from the Framingham Heart Study, for example, demonstrated a direct and continuous relationship between LV mass and the subsequent development of hypertension in previously normotensive subjects [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/21\" class=\"abstract_t\">21</a>]. These observations can be explained in one of three ways:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The progressors may have had a higher mean blood pressure to begin with.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Certain disorders (obesity, for example) increase the risk for both hypertension and LVH through a variety of mechanisms [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/22\" class=\"abstract_t\">22</a>]. Similarly, specific physiologic factors (such as angiotensin II, norepinephrine, epinephrine, increased peripheral and cardiac sympathetic drive [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/23,24\" class=\"abstract_t\">23,24</a>], and endothelin) may both increase blood pressure and LV mass.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The tendency to LVH may be an inherited trait that predisposes to the development of hypertension.</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Role of renin-angiotensin system</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It has been proposed that a <strong>cardiac</strong> renin-angiotensin system and angiotensin-converting enzyme (ACE) activity may be an important determinant of the hypertrophic response [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/25-27\" class=\"abstract_t\">25-27</a>]. Compatible with a role for angiotensin II is the observation that myocardial hypertrophy develops independent of hypertension in transgenic mice, which overexpress the rat angiotensinogen gene, specifically in the heart [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/28\" class=\"abstract_t\">28</a>]. The effect of angiotensin II may be related in part to the promotion of myocardial fibrosis [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=cardiac-remodeling-basic-aspects#H4\" class=\"medical medical_review\">&quot;Cardiac remodeling: Basic aspects&quot;, section on 'Cellular and molecular changes'</a>.)</p><p>It is unclear, however, whether this system is regulated in vivo by in situ renin release or by uptake of circulating renin with subsequent local production of angiotensin II [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/30\" class=\"abstract_t\">30</a>] (see <a href=\"topic.htm?path=actions-of-angiotensin-ii-on-the-heart\" class=\"medical medical_review\">&quot;Actions of angiotensin II on the heart&quot;</a>). Furthermore, although angiotensin II may promote the development of pressure-overload cardiac hypertrophy, studies in angiotensin II type 1 receptor knockout mice have shown that angiotensin II signaling via this receptor is not essential for this process to occur [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/31\" class=\"abstract_t\">31</a>].</p><p>A study in humans that evaluated correlates of LV mass in 84 young healthy subjects aged 16 to 24 provided findings compatible with a direct role for angiotensin II in the development of LVH [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/32\" class=\"abstract_t\">32</a>]. Regression analysis showed that plasma angiotensin II, renin, and ACE levels correlated significantly with LV mass, with the most important component being angiotensin II levels (p&lt;0.001). This relationship was independent of systolic blood pressure and body size.</p><p>The importance of angiotensin II in the development of LVH in hypertensive patients is also suggested indirectly by the following observations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antihypertensive therapy with an ACE inhibitor or angiotensin II receptor blocker (ARB) more predictably causes regression of LVH than beta blockers (<a href=\"image.htm?imageKey=NEPH%2F82558\" class=\"graphic graphic_figure graphicRef82558 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/33\" class=\"abstract_t\">33</a>]. (See <a href=\"topic.htm?path=clinical-implications-and-treatment-of-left-ventricular-hypertrophy-in-hypertension#H4\" class=\"medical medical_review\">&quot;Clinical implications and treatment of left ventricular hypertrophy in hypertension&quot;, section on 'Effect of antihypertensive therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with atherosclerotic renovascular disease (and presumably elevated angiotensin II), have a significantly greater LV mass and a higher prevalence of LVH than control individuals with similar blood pressures [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/34\" class=\"abstract_t\">34</a>].</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Role of endothelin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Studies in experimental animals suggest that endothelin plays a role in the development of myocardial hypertrophy in response to elevated pressure [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/35\" class=\"abstract_t\">35</a>]. As an example, the use of a specific endothelin receptor antagonist prevented the development of hypertrophy without affecting pressure-loading conditions [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/36\" class=\"abstract_t\">36</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Role of heterotrimeric G proteins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many of the hormones and neurotransmitters implicated in the initiation and exacerbation of myocardial hypertrophy, including angiotensin II and endothelin, bind to cell membrane receptors, which couple to a subset of intracellular heterotrimeric G proteins, the G(q) subclass. Direct evidence for the importance of this subclass is provided by the phenotype of transgenic mice, which selectively overexpress the carboxyl-terminal peptide of the alpha subunit G(q) [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/37\" class=\"abstract_t\">37</a>]. This peptide competes with endogenously expressed G proteins, thereby inhibiting intracellular signaling of coupled cell surface receptors. In response to surgically induced pressure overload, transgenic animals develop significantly less myocardial hypertrophy compared with control mice.</p><p class=\"headingAnchor\" id=\"H1543240156\"><span class=\"h2\">Role of cardiac sodium-potassium pumps</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Studies in experimental animals have demonstrated that cardiac alpha-2 sodium (Na-K-ATPase) pumps may play a central role in the development of LVH. When mice are exposed to extreme afterload, LVH is attenuated in those with mutant, knockout, or overexpressed ouabain-resistant Na-K-ATPase pumps [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/38-40\" class=\"abstract_t\">38-40</a>]. This effect is independent of systemic hypertension [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/41\" class=\"abstract_t\">41</a>]. The pathways linking these pumps, their high-affinity ligand ouabain, and LVH are yet to be elucidated.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Genetic tendency to LVH</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The findings that LVH may precede hypertension and that patients with similar degrees of hypertension may have marked differences in LV mass suggest that genetic factors can both promote and retard the development of LVH. Genetic studies in patients with hypertension support the role of the renin-angiotensin system in the development of LVH (see <a href=\"#H4\" class=\"local\">'Role of renin-angiotensin system'</a> above):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A &quot;pro-LVH&quot; genotype consisting of polymorphisms in five renin-angiotensin-aldosterone-system components was associated with higher LV mass and interventricular septal thickness in the general population, as well as in those with hypertrophic cardiomyopathy [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/42\" class=\"abstract_t\">42</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Middle-aged men with the DD genotype of the <em>ACE</em> gene, which is associated with higher tissue and plasma levels of ACE, are at increased risk for LVH [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/43\" class=\"abstract_t\">43</a>]. The increased risk associated with the DD genotype has also been shown in patients who have recently undergone renal transplantation [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/44\" class=\"abstract_t\">44</a>]. (See <a href=\"topic.htm?path=actions-of-angiotensin-ii-on-the-heart#H4\" class=\"medical medical_review\">&quot;Actions of angiotensin II on the heart&quot;, section on 'ACE gene polymorphism'</a>.)</p><p/><p>An additional genetic abnormality associated with the development of LVH is bradykinin receptor B2 gene (<em>BDKRB2</em>) polymorphism. Among subjects undergoing physical training, those with a 9-base pair (bp) deletion of the receptor gene (+9) had lower concentrations of bradykinin and bradykinin receptor and a greater degree of LVH compared with those without this deletion (-9) [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/45\" class=\"abstract_t\">45</a>]. The degree of LVH was greatest in those with the DD genotype of the <em>ACE</em> gene and the <span class=\"nowrap\">+9/+9</span> genotype of the <em>BDKRB2</em> gene. Since ACE inhibitors cause regression of LVH, the effect may be mediated in part by increased kinin levels (ACE is also a kininase).</p><p>Overexpression of the gene responsible for protein kinase C has also been implicated in the development of pathologic hypertrophy. Protein kinase C comprises a family of <span class=\"nowrap\">serine/threonine</span> kinases that influence a variety of cellular functions, including proteins in the sarcolemma and sarcoplasmic reticulum that regulate calcium homeostasis, sarcomeric proteins that influence the calcium sensitivity of the contractile machinery, modulation of cardiac gene expression, and the development of hypertrophy [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/46\" class=\"abstract_t\">46</a>]. In one transgenic animal model, overexpression of protein kinase C in an adult animal resulted in progressive LVH and impaired diastolic relaxation [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"topic.htm?path=cellular-mechanisms-of-diastolic-dysfunction\" class=\"medical medical_review\">&quot;Cellular mechanisms of diastolic dysfunction&quot;</a>.)</p><p>There is also evidence from large population-based studies of an increased tendency to LVH in blacks, independent of body composition [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/48,49\" class=\"abstract_t\">48,49</a>]. As an example, in one study of 1335 black and 858 white participants, the prevalence of LVH indexed for fat free mass was 8 and 3 percent among black and white women, respectively, and 8 and 5 percent among black and white men, respectively [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/49\" class=\"abstract_t\">49</a>]. It is unclear, however, whether this is due to genetic <span class=\"nowrap\">and/or</span> environmental factors (see <a href=\"topic.htm?path=hypertensive-complications-in-blacks\" class=\"medical medical_review\">&quot;Hypertensive complications in blacks&quot;</a>). Hypertensive women also have a greater prevalence of LVH than men with the same degree of blood pressure elevation. Furthermore, LVH in blacks and women may be associated with a greater increase in the relative risk of death than in white men [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/50,51\" class=\"abstract_t\">50,51</a>].</p><p>There is also experimental evidence supporting variable susceptibility, possibly genetic, to the development of LVH and associated myocardial dysfunction. The results of one report suggested that variations in the set point for regulating myocardial growth may be important [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/52\" class=\"abstract_t\">52</a>], while a study in the spontaneously hypertensive rat found a genetic locus on chromosome 2 that affected relative LV mass independent of blood pressure [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/53\" class=\"abstract_t\">53</a>].</p><p class=\"headingAnchor\" id=\"H3005304488\"><span class=\"h2\">Micro RNAs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>MicroRNAs (miRNA) constitute a class of noncoding RNAs that play a key role in the regulation of gene expression. In addition to their role in post-processing transcribed proteins, miRNAs have also been implicated in a number of diseases. A family of circulating miRNAs (ie, miRNA29) is present in higher concentrations in hypertensive patients with LVH compared with hypertensive patients who do not have LVH [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/54\" class=\"abstract_t\">54</a>]. Despite this association of miRNA29 with LVH, a causal or prognostic role has not been elucidated.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Impact of coronary artery disease or valvular disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among hypertensive patients, the degree of LVH may be increased by concurrent coronary disease or valvular disease. In an echocardiographic study of 963 patients with LVH, those with coronary disease had larger LV internal dimensions, greater LV mass, a lower ejection fraction, and higher end-systolic wall stress compared with those without coronary disease [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/55\" class=\"abstract_t\">55</a>].</p><p class=\"headingAnchor\" id=\"H3219300290\"><span class=\"h2\">Other factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other factors that may have a role in the pathogenesis of LVH in hypertension include the inflammatory cytokine interleukin (IL)-6, <span class=\"nowrap\">calcium/calmodulin-dependent</span> protein kinase II, signal transducer and activator of transcription 3 [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/56\" class=\"abstract_t\">56</a>], and some rare copy number variants [<a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/57\" class=\"abstract_t\">57</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Left ventricular hypertrophy (LVH) is a common finding in patients with fixed or borderline hypertension and can be diagnosed either by electrocardiography (ECG) or by echocardiography. Echocardiography is more sensitive and is the procedure of choice. If echocardiography is unavailable or too expensive, appropriate ECG criteria can be used to detect increased LV mass. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LV hypertrophy is defined as an increase in the mass of the left ventricle, which can be secondary to an increase in wall thickness, an increase in cavity size, or both. LVH as a consequence of hypertension usually presents with an increase in wall thickness, with or without an increase in cavity size. The estimation of LV mass is commonly derived from LV measurements obtained by 2D echocardiography. The American Society of Echocardiography, with the European Association of Echocardiography, has issued criteria for LVH. (See <a href=\"#H2\" class=\"local\">'Definition'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The development of LVH, as detected by echocardiography, is an early response to hypertension. Risk factors for the development of LVH include exaggerated transient elevations in blood pressure during mental stress or exercise, a high percentage of pressures above <span class=\"nowrap\">135/85</span> during the day and <span class=\"nowrap\">120/80</span> mmHg at night, and nocturnal hypertension (in which the expected nighttime reduction in blood pressure is not seen). (See <a href=\"#H3\" class=\"local\">'Pathogenesis of LVH in hypertension'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LV mass may be increased <strong>prior</strong> to the development of overt hypertension. This observation may be explained by the fact that the same factors, such as angiotensin II, norepinephrine, epinephrine, increased peripheral and cardiac sympathetic drive, and endothelin, promote both hypertension and LVH. Alternatively the tendency to LVH may be an inherited trait that predisposes to the development of hypertension. (See <a href=\"#H3\" class=\"local\">'Pathogenesis of LVH in hypertension'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A variety of factors, such as the renin-angiotensin system and genetic predisposition, have been implicated in the pathogenesis of LVH in patients with hypertension. (See <a href=\"#H3\" class=\"local\">'Pathogenesis of LVH in hypertension'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H3004222882\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Norman M Kaplan, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/1\" class=\"nounderline abstract_t\">Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992; 327:998.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/2\" class=\"nounderline abstract_t\">Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000; 102:470.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/3\" class=\"nounderline abstract_t\">Devereux RB. Is the electrocardiogram still useful for detection of left ventricular hypertrophy? Circulation 1990; 81:1144.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/4\" class=\"nounderline abstract_t\">Liebson PR, Grandits G, Prineas R, et al. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1993; 87:476.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/5\" class=\"nounderline abstract_t\">de Vries SO, Heesen WF, Beltman FW, et al. Prediction of the left ventricular mass from the electrocardiogram in systemic hypertension. Am J Cardiol 1996; 77:974.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/6\" class=\"nounderline abstract_t\">Norman JE Jr, Levy D. Improved electrocardiographic detection of echocardiographic left ventricular hypertrophy: results of a correlated data base approach. J Am Coll Cardiol 1995; 26:1022.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/7\" class=\"nounderline abstract_t\">Messerli FH, Rimoldi SF, Bangalore S. The Transition From Hypertension to&nbsp;Heart&nbsp;Failure: Contemporary Update. JACC Heart Fail 2017; 5:543.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/8\" class=\"nounderline abstract_t\">Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28:1.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/9\" class=\"nounderline abstract_t\">Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25:879.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/10\" class=\"nounderline abstract_t\">Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995; 25:871.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/11\" class=\"nounderline abstract_t\">van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990; 82:848.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/12\" class=\"nounderline abstract_t\">Jain A, Avendano G, Dharamsey S, et al. Left ventricular diastolic function in hypertension and role of plasma glucose and insulin. Comparison with diabetic heart. Circulation 1996; 93:1396.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/13\" class=\"nounderline abstract_t\">Okin PM, Devereux RB, Nieminen MS, et al. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 2004; 44:48.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/14\" class=\"nounderline abstract_t\">Fragola PV, Colivicchi F, Fabrizi E, et al. Assessment of left ventricular hypertrophy in patients with essential hypertension. A rational basis for the electrocardiogram. Am J Hypertens 1993; 6:164.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/15\" class=\"nounderline abstract_t\">Okin PM, Devereux RB, Nieminen MS, et al. Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point. J Am Coll Cardiol 2001; 38:514.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/16\" class=\"nounderline abstract_t\">Daniels SD, Meyer RA, Loggie JM. Determinants of cardiac involvement in children and adolescents with essential hypertension. Circulation 1990; 82:1243.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/17\" class=\"nounderline abstract_t\">Schnall PL, Pieper C, Schwartz JE, et al. The relationship between 'job strain,' workplace diastolic blood pressure, and left ventricular mass index. Results of a case-control study. JAMA 1990; 263:1929.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/18\" class=\"nounderline abstract_t\">Parati G, Stergiou G, O'Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014; 32:1359.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/19\" class=\"nounderline abstract_t\">Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008; 51:55.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/20\" class=\"nounderline abstract_t\">Devereux RB, Pickering TG, Harshfield GA, et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 1983; 68:470.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/21\" class=\"nounderline abstract_t\">Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 1994; 90:179.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/22\" class=\"nounderline abstract_t\">Brady TM. The Role of Obesity in the Development of Left Ventricular Hypertrophy Among Children and Adolescents. Curr Hypertens Rep 2016; 18:3.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/23\" class=\"nounderline abstract_t\">Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 2001; 38:1711.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/24\" class=\"nounderline abstract_t\">Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/25\" class=\"nounderline abstract_t\">Re RN. Intracellular renin and the nature of intracrine enzymes. Hypertension 2003; 42:117.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/26\" class=\"nounderline abstract_t\">Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153:937.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/27\" class=\"nounderline abstract_t\">Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75:977.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/28\" class=\"nounderline abstract_t\">Mazzolai L, Nussberger J, Aubert JF, et al. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 1998; 31:1324.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/29\" class=\"nounderline abstract_t\">Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant 2006; 21:20.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/30\" class=\"nounderline abstract_t\">Danser AH, van Kats JP, Admiraal PJ, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994; 24:37.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/31\" class=\"nounderline abstract_t\">Harada K, Komuro I, Shiojima I, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 1998; 97:1952.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/32\" class=\"nounderline abstract_t\">Harrap SB, Dominiczak AF, Fraser R, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996; 93:1148.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/33\" class=\"nounderline abstract_t\">Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/34\" class=\"nounderline abstract_t\">Wright JR, Shurrab AE, Cooper A, et al. Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol 2005; 16:2746.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/35\" class=\"nounderline abstract_t\">Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation 1991; 84:1457.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/36\" class=\"nounderline abstract_t\">Ichikawa KI, Hidai C, Okuda C, et al. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J Am Coll Cardiol 1996; 27:1286.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/37\" class=\"nounderline abstract_t\">Akhter SA, Luttrell LM, Rockman HA, et al. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998; 280:574.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/38\" class=\"nounderline abstract_t\">Correll RN, Eder P, Burr AR, et al. Overexpression of the Na+/K+ ATPase &alpha;2 but not &alpha;1 isoform attenuates pathological cardiac hypertrophy and remodeling. Circ Res 2014; 114:249.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/39\" class=\"nounderline abstract_t\">Wansapura AN, Lasko VM, Lingrel JB, Lorenz JN. Mice expressing ouabain-sensitive &alpha;1-Na,K-ATPase have increased susceptibility to pressure overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2011; 300:H347.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/40\" class=\"nounderline abstract_t\">Rindler TN, Lasko VM, Nieman ML, et al. Knockout of the Na,K-ATPase &alpha;2-isoform in cardiac myocytes delays pressure overload-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol 2013; 304:H1147.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/41\" class=\"nounderline abstract_t\">Blaustein MP. How does pressure overload cause cardiac hypertrophy and dysfunction? High-ouabain affinity cardiac Na+ pumps are crucial. Am J Physiol Heart Circ Physiol 2017; 313:H919.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/42\" class=\"nounderline abstract_t\">Ortlepp JR, Vosberg HP, Reith S, et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart 2002; 87:270.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/43\" class=\"nounderline abstract_t\">Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330:1634.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/44\" class=\"nounderline abstract_t\">Hern&aacute;ndez D, Lacalzada J, Rufino M, et al. Prediction of left ventricular mass changes after renal transplantation by polymorphism of the angiotensin-converting-enzyme gene. Kidney Int 1997; 51:1205.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/45\" class=\"nounderline abstract_t\">Brull D, Dhamrait S, Myerson S, et al. Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet 2001; 358:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/46\" class=\"nounderline abstract_t\">Newton AC, Antal CE, Steinberg SF. Protein kinase C mechanisms that contribute to cardiac remodelling. Clin Sci (Lond) 2016; 130:1499.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/47\" class=\"nounderline abstract_t\">Bowman JC, Steinberg SF, Jiang T, et al. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 1997; 100:2189.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/48\" class=\"nounderline abstract_t\">Kizer JR, Arnett DK, Bella JN, et al. Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension 2004; 43:1182.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/49\" class=\"nounderline abstract_t\">Drazner MH, Dries DL, Peshock RM, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension 2005; 46:124.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/50\" class=\"nounderline abstract_t\">Liao Y, Cooper RS, McGee DL, et al. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995; 273:1592.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/51\" class=\"nounderline abstract_t\">Levy D, Garrison RJ, Savage DD, et al. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 1989; 110:101.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/52\" class=\"nounderline abstract_t\">Koide M, Nagatsu M, Zile MR, et al. Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. Circulation 1997; 95:1601.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/53\" class=\"nounderline abstract_t\">Innes BA, McLaughlin MG, Kapuscinski MK, et al. Independent genetic susceptibility to cardiac hypertrophy in inherited hypertension. Hypertension 1998; 31:741.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/54\" class=\"nounderline abstract_t\">Huang Y, Tang S, Huang C, et al. Circulating miRNA29 family expression levels in patients with essential hypertension as potential markers for left ventricular hypertrophy. Clin Exp Hypertens 2017; 39:119.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/55\" class=\"nounderline abstract_t\">Zabalgoitia M, Berning J, Koren MJ, et al. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study). Am J Cardiol 2001; 88:646.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/56\" class=\"nounderline abstract_t\">Zhao L, Cheng G, Jin R, et al. Deletion of Interleukin-6 Attenuates Pressure Overload-Induced Left Ventricular Hypertrophy and Dysfunction. Circ Res 2016; 118:1918.</a></li><li><a href=\"https://www.uptodate.com/contents/definition-and-pathogenesis-of-left-ventricular-hypertrophy-in-hypertension/abstract/57\" class=\"nounderline abstract_t\">Boon-Peng H, Mat Jusoh JA, Marshall CR, et al. Rare Copy Number Variants Identified Suggest the Regulating Pathways in Hypertension-Related Left Ventricular Hypertrophy. PLoS One 2016; 11:e0148755.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3821 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H9\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">DEFINITION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOGENESIS OF LVH IN HYPERTENSION</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Role of renin-angiotensin system</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Role of endothelin</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Role of heterotrimeric G proteins</a></li><li><a href=\"#H1543240156\" id=\"outline-link-H1543240156\">Role of cardiac sodium-potassium pumps</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Genetic tendency to LVH</a></li><li><a href=\"#H3005304488\" id=\"outline-link-H3005304488\">Micro RNAs</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Impact of coronary artery disease or valvular disease</a></li><li><a href=\"#H3219300290\" id=\"outline-link-H3219300290\">Other factors</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">SUMMARY</a></li><li><a href=\"#H3004222882\" id=\"outline-link-H3004222882\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEPH/3821|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=NEPH/82558\" class=\"graphic graphic_figure\">- Regression of LV hypertrophy with antihypertensive therapy</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=actions-of-angiotensin-ii-on-the-heart\" class=\"medical medical_review\">Actions of angiotensin II on the heart</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ambulatory-and-home-blood-pressure-monitoring-and-white-coat-hypertension-in-adults\" class=\"medical medical_review\">Ambulatory and home blood pressure monitoring and white coat hypertension in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiac-remodeling-basic-aspects\" class=\"medical medical_review\">Cardiac remodeling: Basic aspects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cellular-mechanisms-of-diastolic-dysfunction\" class=\"medical medical_review\">Cellular mechanisms of diastolic dysfunction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-implications-and-treatment-of-left-ventricular-hypertrophy-in-hypertension\" class=\"medical medical_review\">Clinical implications and treatment of left ventricular hypertrophy in hypertension</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-heart-failure-with-preserved-ejection-fraction\" class=\"medical medical_review\">Clinical manifestations and diagnosis of heart failure with preserved ejection fraction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=electrocardiographic-diagnosis-of-left-ventricular-hypertrophy\" class=\"medical medical_review\">Electrocardiographic diagnosis of left ventricular hypertrophy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypertensive-complications-in-blacks\" class=\"medical medical_review\">Hypertensive complications in blacks</a></li></ul></div></div>","javascript":null}